RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $762

Benzinga Newsdesk www.benzinga.com Negative 90.0%

Neg 90% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and lowers the price target from $779 to $762.